LATEST
Tue, Nov 17, 2026
Loading weather...
Markets

FDA Clears Novartis Drug Cosentyx As Steroid Alternative for Inflammatory Pain Causing Stiff Shoulders

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s (NYSE:NVS) Cosentyx (secukinumab) 150 mg ...

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s (NYSE:NVS) Cosentyx (secukinumab) 150 mg to treat adults with polymyalgia rheumatica (PMR) who respond inadequately to corticosteroids or cannot tolerate a corticosteroid taper. The regulatory decision establishes Cosentyx as the first and only anti-interleukin-17 (anti-IL-17) biologic for PMR, giving rheumatologists an alternative to long-term steroid therapy backed by...

SOURCE: Benzinga
ORIGINAL REPORT: Click here
DHALLO EDITORIAL STATUS: Aggregated & reviewed
Have feedback on this article?Report error or suggestion

Read More from Markets

Novo Nordisk Highlights Protective Bone Biomarkers For CagriSema And Pediatric BMI Drops

Novo Nordisk AG (NYSE:NVO) presented new data at ObesityWeek 2026 demonstrating ...

Read Article »

Home Depot Taps CFO Richard McPhail to Lead, Narrows Profit Outlook

The Home Depot Inc. (NYSE:HD) stock fell Tuesday after the home improvement reta...

Read Article »

Michael Saylor Compliments Twenty One as Bitcoin Treasury Race Heats Up

Twenty One (NYSE:XXI) bought 154.32 Bitcoin (CRYPTO: BTC) for about $10 million ...

Read Article »
Return to Front Page

5 minutes. The news that matters.

Get the most important stories of the day, without having to browse hundreds of articles.